> Back to EJC

 

Previous editions of EJC News Focus

  • November 2011
    Gordon Mills assesses the challenges we face in developing personalised medicine.
  • October 2011
    Richard Sullivan explains why the spiralling rise in healthcare costs associated with cancer is unsustainable.
  • September 2011
    Anne-Lise Borresen-Dale discusses key themes to emerge at the European Multidisciplinary Cancer Congress in Stockholm.
  • August 2011
    Jean-Charles Soria, EJC's Drug Development Editor, on the need for a new consensus on assessing toxicities.
  • July 2011
    EJC editor-in-chief Alexander Eggermont on recent advances in melanoma treatment.
  • June 2011
    Jean-Yves Blay discusses how EORTC is adapting to the new environment for research.
  • April/May 2011
    Cora Sternberg reveals exciting developments in the treatment of prostate cancer.
  • March 2011
    EJC's editor for gastrointestinal cancers, Eric van Cutsem, discusses the disappointing findings of recent trials of bevacizumab in colon cancer
  • February 2011
    Michel Coleman from the London School of Hygiene and Tropical Medicine discusses a comparison of cancer survival rates in different countries.
  • January 2011
    Jan Willem Coebergh discusses a paper relating to the NELSON lung cancer trial.

EJC News Focus – July 2011

Loading EJC News Focus video

 

The July issue of EJC News Focus is an interview with our editor-in-chief, melanoma expert Alexander Eggermont. Advances in the treatment of melanoma stole the limelight at the recent ASCO Annual meeting; after decades of unsuccessful research, data was presented showing that two drugs with completely different mechanisms of action – ipilimumab and vemurafenib – could improve overall survival in advanced disease. EJC News Focus explores these and the other developments in the pipeline that look set to usher in a new era in melanoma research.

See also:
EJC Review: New Drugs in Melanoma: It’s a whole new world. AMM Eggermont, Caroline Robert. In press
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma: 10.1056/NEJMoa1104621
Improved survival with vemurafenib in melanoma with BRAF V600E mutation: 10.1056/NEJMoa1103782